213 related articles for article (PubMed ID: 23651189)
1. Integration of epidemiology, immunobiology, and translational research for brain tumors.
Okada H; Scheurer ME; Sarkar SN; Bondy ML
Ann N Y Acad Sci; 2013 May; 1284(1):17-23. PubMed ID: 23651189
[TBL] [Abstract][Full Text] [Related]
2. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
Fujita M; Scheurer ME; Decker SA; McDonald HA; Kohanbash G; Kastenhuber ER; Kato H; Bondy ML; Ohlfest JR; Okada H
Clin Cancer Res; 2010 Jul; 16(13):3409-19. PubMed ID: 20472682
[TBL] [Abstract][Full Text] [Related]
3. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
4. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
[TBL] [Abstract][Full Text] [Related]
5. Immunobiology and immunotherapeutic targeting of glioma stem cells.
Madany M; Thomas TM; Edwards L; Yu JS
Adv Exp Med Biol; 2015; 853():139-66. PubMed ID: 25895711
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy approaches for malignant glioma from 2007 to 2009.
Johnson LA; Sampson JH
Curr Neurol Neurosci Rep; 2010 Jul; 10(4):259-66. PubMed ID: 20424975
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.
Kohanbash G; Okada H
Immunol Invest; 2012; 41(6-7):658-79. PubMed ID: 23017140
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Zhang H; Tian M; Xiu C; Wang Y; Tang G
Oncol Res; 2013; 20(10):447-55. PubMed ID: 24308155
[TBL] [Abstract][Full Text] [Related]
9. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
10. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
11. Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies.
Scheurer ME; Amirian ES; Davlin SL; Rice T; Wrensch M; Bondy ML
Int J Cancer; 2011 Nov; 129(9):2290-6. PubMed ID: 21190193
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for glioma: Current management and future application.
Xu S; Tang L; Li X; Fan F; Liu Z
Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
[TBL] [Abstract][Full Text] [Related]
13. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
14. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
Hasan MN; Luo L; Ding D; Song S; Bhuiyan MIH; Liu R; Foley LM; Guan X; Kohanbash G; Hitchens TK; Castro MG; Zhang Z; Sun D
Theranostics; 2021; 11(3):1295-1309. PubMed ID: 33391535
[No Abstract] [Full Text] [Related]
15. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.
Kohanbash G; McKaveney K; Sakaki M; Ueda R; Mintz AH; Amankulor N; Fujita M; Ohlfest JR; Okada H
Cancer Res; 2013 Nov; 73(21):6413-23. PubMed ID: 24030977
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and molecular pathology of glioma.
Schwartzbaum JA; Fisher JL; Aldape KD; Wrensch M
Nat Clin Pract Neurol; 2006 Sep; 2(9):494-503; quiz 1 p following 516. PubMed ID: 16932614
[TBL] [Abstract][Full Text] [Related]
17. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
Du B; Waxman DJ
Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
[TBL] [Abstract][Full Text] [Related]
18. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages.
Wang H; Zhang L; Zhang IY; Chen X; Da Fonseca A; Wu S; Ren H; Badie S; Sadeghi S; Ouyang M; Warden CD; Badie B
Clin Cancer Res; 2013 Jul; 19(14):3764-75. PubMed ID: 23719262
[TBL] [Abstract][Full Text] [Related]
19. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM
Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934
[TBL] [Abstract][Full Text] [Related]
20. The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.
Jiao H; Yang B; Guan F; Li J; Shan H; Song L; Hu X; Liang S; Du Y; Jiang C
Neurol Res; 2011 May; 33(4):405-14. PubMed ID: 21535940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
